Plasma Cystatin C service
The Cystatin C assay is part of a new service by the Department
of Clinical Biochemistry. This is a major quality improvement for
patients in whom we could not previously reliably check kidney
function using traditional methods. Patients with Spina Bifida,
amputees, muscular dystrophies, anorexic patients, cachectic
patients and those with significant severe jaundice will
Indications for use of Cystatin C assay
The available evidence suggests that measurement of plasma/serum
Cystatin C can provide valuable additional information on renal
function in specific settings or patient groups.
- Patients with very high levels of plasma/serum bilirubin e.g.
Hepatic VOD; Hepatorenal syndrome. Cut-offs for Bilirubin > 342
μmol/L paediatrics; 500 μmol/L adults
- Patients with low muscle mass e.g.
- Duchenne, Becker or other muscular dystrophy
- Pervasive refusal disorders where weight for height is
- Pervasive refusal disorders where plasma creatinine is >75%
- Spina Bifida ± renal insufficiency
- Patients where plasma/serum creatinine concentration is
discordant with clinical signs and symptoms suggestive of renal
However, in non-jaundiced patients with normal muscle mass there
is evidence that data from the Cystatin C assay does not offer any
benefits to patient management over standard plasma/serum
creatinine measurement. It is therefore not recommended for general
use as a marker of renal function.
Download detailed information on this service,
including reference ranges (PDF, 289KB)
Call 0161 701 2233 for more information or email: email@example.com or firstname.lastname@example.org